MET and hepatocellular carcinoma: This single-patient case shows that acquired resistance to crizotinib in MET-amplified HCC can arise via two non-exclusive routes: attenuation or loss of the original MET driver and the emergence of putative bypass alterations (HGF p.G401A and NF1 p.M546L).